Pascal Finetti
Overview
Explore the profile of Pascal Finetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
6426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boutanquoi P, Pommerolle L, Dondaine L, Tanguy J, Bellaye P, Biziorek L, et al.
Br J Pharmacol
. 2025 Mar;
PMID: 40033950
Background And Purpose: Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by fibroblast activation and abnormal accumulation of extracellular matrix in the lungs. We previously demonstrated the importance of...
2.
Guille A, Adelaide J, Finetti P, Andre F, Birnbaum D, Mamessier E, et al.
Brief Bioinform
. 2025 Jan;
26(1).
PMID: 39828270
By identifying somatic mutations, whole-exome sequencing (WES) has become a technology of choice for the diagnosis and guiding treatment decisions in many cancers. Despite advances in the field of somatic...
3.
Kfoury M, Finetti P, Mamessier E, Bertucci F, Sabatier R
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596024
Antibody-drug conjugates targeting folate receptor alpha (FRα) are a promising treatment for platinum-resistant ovarian cancer (OC) with high FRα expression. Challenges persist in accurately assessing FRα expression levels. Our study...
4.
Bertucci F, Guille A, Lerebours F, Ceccarelli M, Syed N, Adelaide J, et al.
J Transl Med
. 2024 Oct;
22(1):969.
PMID: 39465437
Background: Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature...
5.
de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaide J, Finetti P, et al.
Mol Oncol
. 2024 Jun;
18(10):2586-2600.
PMID: 38923749
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter...
6.
Bertucci F, Lerebours F, Ceccarelli M, Guille A, Syed N, Finetti P, et al.
J Transl Med
. 2024 Apr;
22(1):374.
PMID: 38637846
Background: Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of...
7.
Hussain Z, Bertran T, Finetti P, Lohmann E, Mamessier E, Bidaut G, et al.
Cell Commun Signal
. 2024 Jan;
22(1):1.
PMID: 38167013
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a clinically challenging cancer, mainly due to limited therapeutic options and the presence of a highly prominent tumor microenvironment (TME), facilitating tumor progression. The...
8.
Miallot R, Millet V, Roger A, Fenouil R, Tardivel C, Martin J, et al.
Life Sci Alliance
. 2023 Nov;
7(2).
PMID: 38030222
No abstract available.
9.
Miallot R, Millet V, Roger A, Fenouil R, Tardivel C, Martin J, et al.
Life Sci Alliance
. 2023 Oct;
6(12).
PMID: 37833072
The tumor microenvironment is a dynamic network of stromal, cancer, and immune cells that interact and compete for resources. We have previously identified the Vanin1 pathway as a tumor suppressor...
10.
Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, et al.
J Transl Med
. 2023 Sep;
21(1):637.
PMID: 37726776
Background: Anti-PD1/PDL1 immune checkpoint inhibitors (ICI) transformed the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However, the response rate remains disappointing and toxicity may be life-threatening, making...